BioSpace News Archive

Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage biotechnology company developing multifunctional biotherapeutics, today announced positive topline results from the pivotal Phase 2b HERIZON-BTC-01 open-label, single-arm clinical trial investigating zanidatamab.

Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch ® 3D genomics platform, announced that its senior leadership will be in San Francisco during the 41st Annual J.P. Morgan Healthcare Conference, Jan 9-12 2023.

BioInvent International AB today announces the inclusion of the first patient in a Phase 1 trial with a subcutaneous formulation of its lead drug candidate, the novel anti-FcyRIIB antibody BI-1206.

Biogen Inc. (Nasdaq: BIIB) announced that it has reached an agreement with Genentech, a member of the Roche Group, related to the commercialization and sharing of economics for glofitamab.

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that Chairman of the Board of Directors, Robert (Bob) A. Ingram, has stepped down due to personal reasons. Existing Board member, Mark Velleca, M.D., Ph.D., has been appointed to succeed Mr. Ingram as the next Chairman.

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company) today announced that Zheng Wei, PhD, Co-Founder and CEO of Connect Biopharma will present a corporate update on January 9, at 9:00 am PST, during the upcoming Biotech Showcase taking place in person January 9 – 11, 2023.

Jiangsu Recbio Technology Co., Ltd. is pleased to announce that, the Group has recently received the clinical trial approval for its novel adjuvanted recombinant shingles vaccine, REC610, from the Food and Drug Administration of the Philippines.

EnginZyme, a green tech company developing biomanufacturing processes for the sustainable manufacturing of everyday products, announced that it had raised €21 million in a Series B financing round.

Spineart, a leading provider of spine surgery implants and eCential Robotics, a growth MedTech company that designs and produces an open system unifying robotics, surgical navigation, and 2D/3D robotic imaging, today announced they entered a long-term collaboration agreement.

Kineta, Inc., a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced the completion of its reverse merger with Yumanity Therapeutics, Inc.